share_log

Independent Non-Executive Director Ting Yuk Wu Sold A Bunch Of Shares In China Resources Medical Holdings

Independent Non-Executive Director Ting Yuk Wu Sold A Bunch Of Shares In China Resources Medical Holdings

獨立非執行董事吳廷玉出售了華潤醫療控股的大量股份
Simply Wall St ·  05/22 07:24

Anyone interested in China Resources Medical Holdings Company Limited (HKG:1515) should probably be aware that the Independent Non-Executive Director, Ting Yuk Wu, recently divested HK$2.6m worth of shares in the company, at an average price of HK$4.41 each. Equally important, that sale actually reduced their holding by a full 100% which hardly makes us feel bullish about the stock.

任何對華潤醫療控股有限公司(HKG: 1515)感興趣的人都應該知道,獨立非執行董事吳丁玉最近以平均每股4.41港元的價格剝離了該公司價值260萬港元的股份。同樣重要的是,那次出售實際上使他們的持股量減少了整整100%,這幾乎使我們對該股感到看漲。

China Resources Medical Holdings Insider Transactions Over The Last Year

華潤醫療控股去年的內幕交易

Notably, that recent sale by Ting Yuk Wu is the biggest insider sale of China Resources Medical Holdings shares that we've seen in the last year. So we know that an insider sold shares at around the present share price of HK$4.27. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. Given that the sale took place at around current prices, it makes us a little cautious but is hardly a major concern.

值得注意的是,Ting Yuk Wu最近的出售是我們去年對華潤醫療控股股票的最大一次內幕出售。因此,我們知道一位內部人士以目前的4.27港元左右的股價出售了股票。儘管內幕拋售是負面的,但對我們來說,如果以較低的價格出售股票,則負面影響更大。鑑於此次出售是以當前價格進行的,這使我們有點謹慎,但並不是一個主要問題。

Ting Yuk Wu sold a total of 1.00m shares over the year at an average price of CN¥4.38. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

吳丁玉全年共出售了100萬股股票,平均價格爲4.38元人民幣。您可以看到下圖所示的去年的內幕交易(公司和個人)。如果你點擊圖表,你可以看到所有的個人交易,包括股價、個人和日期!

insider-trading-volume
SEHK:1515 Insider Trading Volume May 21st 2024
SEHK: 1515 內幕交易量 2024 年 5 月 21 日

If you are like me, then you will not want to miss this free list of small cap stocks that are not only being bought by insiders but also have attractive valuations.

如果你像我一樣,那麼你一定不想錯過這份免費的小盤股清單,這些股票不僅被內部人士買入,而且估值也很有吸引力。

Insider Ownership Of China Resources Medical Holdings

華潤醫療控股的內部所有權

For a common shareholder, it is worth checking how many shares are held by company insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. From looking at our data, insiders own HK$9.6m worth of China Resources Medical Holdings stock, about 0.2% of the company. But they may have an indirect interest through a corporate structure that we haven't picked up on. We prefer to see high levels of insider ownership.

對於普通股股東來說,值得檢查一下公司內部人士持有多少股票。較高的內部所有權通常會使公司領導層更加關注股東的利益。從我們的數據來看,內部人士擁有價值960萬港元的華潤醫療控股股票,約佔該公司0.2%的股份。但是,他們可能會通過我們尚未掌握的公司結構獲得間接利益。我們更願意看到高水平的內部所有權。

What Might The Insider Transactions At China Resources Medical Holdings Tell Us?

華潤醫療控股的內幕交易可能告訴我們什麼?

An insider sold stock recently, but they haven't been buying. And there weren't any purchases to give us comfort, over the last year. Insiders own relatively few shares in the company, and when you consider the sales, we're not particularly excited about the stock. So we're not rushing to buy, to say the least. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing China Resources Medical Holdings. To assist with this, we've discovered 1 warning sign that you should run your eye over to get a better picture of China Resources Medical Holdings.

一位內部人士最近出售了股票,但他們一直沒有買入。在過去的一年裏,沒有任何能讓我們感到安慰的購買。內部人士擁有該公司的股票相對較少,當你考慮銷售情況時,我們對這隻股票並不特別興奮。因此,至少可以說,我們並不急於購買。除了了解正在進行的內幕交易外,確定華潤醫療控股面臨的風險也是有益的。爲了幫助解決這個問題,我們發現了一個警告信號,你應該仔細看看,以更好地了解華潤醫療控股的情況。

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

如果你想看看另一家公司——一家財務狀況可能優越的公司——那麼千萬不要錯過這份免費的股本回報率高、債務低的有趣公司的名單。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

就本文而言,內部人士是指向相關監管機構報告其交易的個人。我們目前只考慮公開市場交易和私下處置的直接利益,不包括衍生品交易或間接權益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論